Arena Pharmaceuticals Company Profile (NASDAQ:ARNA)

About Arena Pharmaceuticals (NASDAQ:ARNA)

Arena Pharmaceuticals logoArena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH). The Company's drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management. The Company's drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. The Company's programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases, and an undisclosed orphan GPCR for central nervous system (CNS) indication(s).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ARNA
  • CUSIP: 04004710
  • Web:
  • Market Cap: $994.23 million
  • Outstanding Shares: 39,220,000
Average Prices:
  • 50 Day Moving Avg: $24.68
  • 200 Day Moving Avg: $18.83
  • 52 Week Range: $11.30 - $27.86
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.57
  • P/E Growth: 0.43
Sales & Book Value:
  • Annual Revenue: $117.73 million
  • Price / Sales: 8.51
  • Book Value: $2.11 per share
  • Price / Book: 12.11
  • EBITDA: $16.71 million
  • Net Margins: -16.27%
  • Return on Equity: -49.87%
  • Return on Assets: -10.82%
  • Debt-to-Equity Ratio: 0.72%
  • Current Ratio: 3.21%
  • Quick Ratio: 3.06%
  • Average Volume: 620,447 shs.
  • Beta: 1.41
  • Short Ratio: 0.54

Frequently Asked Questions for Arena Pharmaceuticals (NASDAQ:ARNA)

What is Arena Pharmaceuticals' stock symbol?

Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA."

When did Arena Pharmaceuticals' stock split? How did Arena Pharmaceuticals' stock split work?

Arena Pharmaceuticals's stock reverse split on Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 16th 2017. An investor that had 100 shares of Arena Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

How were Arena Pharmaceuticals' earnings last quarter?

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) issued its quarterly earnings data on Monday, August, 7th. The company reported ($0.77) EPS for the quarter, missing the Zacks' consensus estimate of ($0.74) by $0.03. The company had revenue of $6.49 million for the quarter, compared to analysts' expectations of $5.58 million. Arena Pharmaceuticals had a negative net margin of 16.27% and a negative return on equity of 49.87%. The business's quarterly revenue was down 31.8% compared to the same quarter last year. During the same period last year, the firm earned ($1.10) EPS. View Arena Pharmaceuticals' Earnings History.

When will Arena Pharmaceuticals make its next earnings announcement?

Arena Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Arena Pharmaceuticals.

Where is Arena Pharmaceuticals' stock going? Where will Arena Pharmaceuticals' stock price be in 2017?

7 equities research analysts have issued 12 month target prices for Arena Pharmaceuticals' stock. Their forecasts range from $19.00 to $60.00. On average, they expect Arena Pharmaceuticals' stock price to reach $38.83 in the next year. View Analyst Ratings for Arena Pharmaceuticals.

What are analysts saying about Arena Pharmaceuticals stock?

Here are some recent quotes from research analysts about Arena Pharmaceuticals stock:

  • 1. Needham & Company LLC analysts commented, "Arena mgmt hosted a conference call yesterday to provide a 2Q17 quarterly corporate update. Company announced positive results from a 61-pt Phase 2 trial of ralinepag in Pulmonary Arterial Hypertension (PAH) in Jul 2017. We await insight into FDA and EMA requirements for registration. Mgmt is not providing specific guidance, but we assume mtgs can be scheduled by YE17. Other upcoming milestones include top-line results from Phase 2 trials of etrasimod in Ulcerative Colitis (YE17) and APD-371 in pain associated with Crohn’s Disease (YE17)." (8/8/2017)
  • 2. Cantor Fitzgerald analysts commented, "We continue to view Phase 2 data as about as good as it gets. Despite facing comparisons with Phase 2 data for a drug, selexipag, that benefited from trial idiosyncrasies (subject randomization imbalances), the improvement in pulmonary vascular resistance (PVR) associated with treatment in the ralinepag Phase 2 trial (-30% vs. placebo and -20% vs. baseline) was at the high end of a range of effects noted to us by a physician knowledgeable in the care of patients with PAH and the development of therapies for it." (7/17/2017)
  • 3. According to Zacks Investment Research, "Arena received a boost with the launch of Belviq XR, a once-daily, extended-release formulation of its only marketed drug, Belviq, in October 2016. Though sales of Belviq have been lackluster so far, the company partnership agreements and efforts to improve Belviq’s performance is impressive. We are encouraged by the company’s cost reduction initiatives to streamline the organization to support its development programs. Moreover, the company’s decision to shift its priorities to its proprietary clinical-stage pipeline is also encouraging. The company recently announced positive results on its PAH candidate, ralinepeg. On the flip side, Arena’s pipeline consists of early-to-mid stage candidates that are still several years from commercialization. Moreover, competition remains intense in the obesity market which has both branded and generic players." (7/4/2017)

Who are some of Arena Pharmaceuticals' key competitors?

Who are Arena Pharmaceuticals' key executives?

Arena Pharmaceuticals' management team includes the folowing people:

  • Amit D. Munshi, President, Chief Executive Officer, Director
  • Kevin R. Lind, Chief Financial Officer, Principal Financial Officer, Executive Vice President, Principal Accounting Officer
  • Steven W. Spector J.D., Executive Vice President, General Counsel, Secretary
  • Vincent E. Aurentz, Executive Vice President and Chief Business Officer
  • Preston S. Klassen M.D., Executive Vice President - Research & Development, Chief Medical Officer
  • Maurice J. Mezzino, Senior Vice President - Corporate Development
  • Tina Susan Nova Ph.D., Lead Independent Director
  • Donald D. Belcher, Director
  • Jayson Dallas M.D., Director
  • Oliver S. Fetzer Ph.D., Director

How do I buy Arena Pharmaceuticals stock?

Shares of Arena Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Arena Pharmaceuticals' stock price today?

One share of Arena Pharmaceuticals stock can currently be purchased for approximately $25.56.

MarketBeat Community Rating for Arena Pharmaceuticals (NASDAQ ARNA)
Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  174 (Vote Outperform)
Underperform Votes:  196 (Vote Underperform)
Total Votes:  370
MarketBeat's community ratings are surveys of what our community members think about Arena Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Arena Pharmaceuticals (NASDAQ:ARNA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.71)
Consensus Price Target: $38.83 (51.93% upside)
Consensus Price Target History for Arena Pharmaceuticals (NASDAQ:ARNA)
Price Target History for Arena Pharmaceuticals (NASDAQ:ARNA)
Analysts' Ratings History for Arena Pharmaceuticals (NASDAQ:ARNA)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/25/2017Cantor FitzgeraldReiterated RatingBuy$37.00HighView Rating Details
8/8/2017Needham & Company LLCReiterated RatingHoldMediumView Rating Details
7/12/2017Wells Fargo & CompanyReiterated RatingMarket Perform$15.00 -> $19.00MediumView Rating Details
7/11/2017Citigroup Inc.Boost Price TargetBuy -> Buy$23.00 -> $37.00LowView Rating Details
7/11/2017Leerink SwannBoost Price TargetOutperform$47.00 -> $53.00HighView Rating Details
7/7/2017JMP SecuritiesUpgradeMarket Perform -> Outperform$27.00 -> $27.00HighView Rating Details
3/16/2017FBR & CoReiterated RatingOutperform$60.00MediumView Rating Details
8/10/2016Jefferies Group LLCReiterated RatingBuyN/AView Rating Details
8/8/2016J P Morgan Chase & CoReiterated RatingHoldN/AView Rating Details
3/2/2016Piper Jaffray CompaniesReiterated RatingBuyN/AView Rating Details
3/1/2016Royal Bank Of CanadaReiterated RatingSector Perform$20.00 -> $15.00N/AView Rating Details
10/28/2015WallachBeth CapitalLower Price TargetBuy$60.00 -> $40.00N/AView Rating Details
(Data available from 10/17/2015 forward)


Earnings History for Arena Pharmaceuticals (NASDAQ:ARNA)
Earnings by Quarter for Arena Pharmaceuticals (NASDAQ:ARNA)
Earnings History by Quarter for Arena Pharmaceuticals (NASDAQ ARNA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.67)N/AView Earnings Details
8/7/2017Q2 2017($0.74)($0.77)$5.58 million$6.49 millionViewN/AView Earnings Details
5/9/2017Q1 2017($0.82)($0.90)$4.84 million$6.60 millionViewN/AView Earnings Details
3/14/2017Q4 2016($0.80)$1.60$14.12 million$85.40 millionViewN/AView Earnings Details
11/7/2016Q316($0.70)($0.50)$13.99 million$19.20 millionViewN/AView Earnings Details
8/8/2016Q216($1.00)($1.10)$10.44 million$9.50 millionViewN/AView Earnings Details
5/9/2016Q116($1.00)($0.90)$9.02 million$9.80 millionViewN/AView Earnings Details
2/29/2016Q415($1.30)($1.30)$8.26 million$7.80 millionViewN/AView Earnings Details
11/10/2015Q315($1.30)($1.10)$8.87 million$9.10 millionViewN/AView Earnings Details
8/5/2015Q215($1.40)($1.10)$10.95 million$9.18 millionViewN/AView Earnings Details
5/11/2015Q115($1.40)($1.00)$10.56 million$12.30 millionViewN/AView Earnings Details
3/2/2015Q414($1.20)($1.50)$10.36 million$9.20 millionViewN/AView Earnings Details
11/3/2014Q314($1.30)($0.50)$10.90 million$8.20 millionViewN/AView Earnings Details
8/1/2014Q2 14($1.10)($1.20)$9.81 million$12.80 millionViewN/AView Earnings Details
5/12/2014Q114($1.00)($1.20)$7.98 million$6.80 millionViewN/AView Earnings Details
2/27/2014Q413$0.20($1.10)$7.00 million$6.50 millionViewN/AView Earnings Details
11/7/2013Q313($1.20)($0.80)$5.30 million$3.60 millionViewN/AView Earnings Details
8/1/2013Q2 2013$1.50$1.80$57.30 million$68.90 millionViewN/AView Earnings Details
4/30/2013Q1 2013$1.10$0.90$50.36 million$2.37 millionViewN/AView Earnings Details
3/4/2013Q4 2012($0.30)($1.00)$21.94 million$1.94 millionViewN/AView Earnings Details
11/6/2012Q312($1.10)($0.70)$3.72 million$1.50 millionViewN/AView Earnings Details
8/9/2012($0.80)($1.20)ViewN/AView Earnings Details
11/9/2011($1.40)($1.60)ViewN/AView Earnings Details
8/9/2011($1.50)($1.60)ViewN/AView Earnings Details
5/10/2011($2.10)($3.50)ViewN/AView Earnings Details
3/11/2011($2.20)($2.30)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Arena Pharmaceuticals (NASDAQ:ARNA)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.64)($0.64)($0.64)
Q3 20171($0.69)($0.69)($0.69)
Q4 20171($0.72)($0.72)($0.72)
(Data provided by Zacks Investment Research)


Dividend History for Arena Pharmaceuticals (NASDAQ:ARNA)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Arena Pharmaceuticals (NASDAQ:ARNA)
Insider Ownership Percentage: 1.88%
Institutional Ownership Percentage: 46.21%
Insider Trades by Quarter for Arena Pharmaceuticals (NASDAQ:ARNA)
Institutional Ownership by Quarter for Arena Pharmaceuticals (NASDAQ:ARNA)
Insider Trades by Quarter for Arena Pharmaceuticals (NASDAQ:ARNA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/12/2017Amit MunshiInsiderBuy25,000$1.19$29,750.00View SEC Filing  
4/26/2017Amit MunshiInsiderBuy50,000$1.41$70,500.00View SEC Filing  
6/13/2016Christine Anna WhiteDirectorSell18,728$1.99$37,268.72View SEC Filing  
3/30/2015Randall E WoodsDirectorSell76,268$4.49$342,443.32View SEC Filing  
3/17/2015Steven W SpectorEVPSell70,000$5.00$350,000.00View SEC Filing  
1/8/2015Steven W SpectorEVPSell45,000$6.26$281,700.00View SEC Filing  
1/7/2015William R Shanahan JrSVPSell50,000$5.49$274,500.00View SEC Filing  
7/1/2014Jack LiefCEOSell223,525$5.85$1,307,621.25View SEC Filing  
6/27/2014Donald D BelcherDirectorSell2,473$5.85$14,467.05View SEC Filing  
5/6/2014Donald BelcherDirectorSell4,176$7.00$29,232.00View SEC Filing  
4/22/2014Harry Hixson, Jr.DirectorSell36,900$6.31$232,839.00View SEC Filing  
4/14/2014Tina Susan NovaDirectorSell35,000$6.22$217,700.00View SEC Filing  
4/1/2014Donald BelcherDirectorSell1,905$6.45$12,287.25View SEC Filing  
4/1/2014William Shanahan, Jr.SVPSell60,000$6.37$382,200.00View SEC Filing  
3/4/2014Steven SpectorEVPSell25,000$7.01$175,250.00View SEC Filing  
1/17/2014Jack LiefCEOSell100,000$7.81$781,000.00View SEC Filing  
1/10/2014Dominic BehanEVPSell33,332$6.25$208,325.00View SEC Filing  
9/10/2013Dominic P BehanEVPSell200,000$6.31$1,262,000.00View SEC Filing  
9/5/2013Steven W SpectorEVPSell20,000$6.54$130,800.00View SEC Filing  
5/21/2013Craig Michael AudetSVPSell83,750$8.00$670,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Arena Pharmaceuticals (NASDAQ:ARNA)
Latest Headlines for Arena Pharmaceuticals (NASDAQ:ARNA)
DateHeadline logoDo This 1 Thing and Lower Your Risk for 13 Types of Cancer - October 15 at 3:50 PM logoArena Pharmaceuticals (ARNA) vs. The Competition Head-To-Head Survey - October 13 at 8:30 PM logoHere's What Lifted Arena Pharmaceuticals, Inc. Stock in September - Motley Fool - October 11 at 3:24 AM logoZacks: Brokerages Anticipate Arena Pharmaceuticals, Inc. (ARNA) Will Post Quarterly Sales of $4.39 Million - October 9 at 6:36 AM logoETFs with exposure to Arena Pharmaceuticals, Inc. : October 4, 2017 - October 4 at 2:05 PM logoOne Thing To Consider Before Buying Arena Pharmaceuticals Inc (ARNA) - October 2 at 9:00 PM logoOrexigen's (OREX) Contrave Sales Improving on Promotions - October 2 at 3:57 PM logoArena Pharmaceuticals, Inc. (ARNA) Given Average Rating of "Buy" by Brokerages - September 30 at 8:53 AM logoArena Pharmaceuticals (ARNA) Presents At Ladenburg Thalmann 2017 Healthcare Conference - Slideshow - September 27 at 7:55 PM logoCantor Fitzgerald Reaffirms "Buy" Rating for Arena Pharmaceuticals, Inc. (ARNA) - September 25 at 4:06 PM logoArena Pharmaceuticals (ARNA) & Its Competitors Head to Head Comparison - September 24 at 8:42 AM logoETFs with exposure to Arena Pharmaceuticals, Inc. : September 22, 2017 - September 22 at 1:22 PM logo-$0.69 Earnings Per Share Expected for Arena Pharmaceuticals, Inc. (ARNA) This Quarter - September 18 at 4:28 PM logoAnalyzing Arena Pharmaceuticals (ARNA) and Its Peers - September 14 at 12:24 PM logoETFs with exposure to Arena Pharmaceuticals, Inc. : September 12, 2017 - September 12 at 1:58 AM logoCramer's lightning round: Allergan's in a torturous situa... - September 11 at 8:56 PM logoArena Pharmaceuticals, Inc. :ARNA-US: Earnings Analysis: Q2, 2017 By the Numbers : September 8, 2017 - September 8 at 4:25 PM logoJ&J (JNJ) PAH Drug's U.S. Label Expanded for Pediatric Use - September 7 at 9:07 PM logoArena Pharmaceuticals (ARNA) Presents At 6th Annual Liolios Gateway Conference - Slideshow - September 7 at 9:07 PM logoArena Pharmaceuticals (ARNA) Down 1.5% Since Earnings Report: Can It Rebound? - Nasdaq - September 7 at 4:05 PM logoArena Pharmaceuticals (ARNA) Down 1.5% Since Earnings Report: Can It Rebound? - September 7 at 4:05 PM logoArena Pharmaceuticals' (ARNA) CEO Amit Munshi Presents at 2017 Wells Fargo Healthcare Brokers Conference ... - Seeking Alpha - September 6 at 9:01 PM logoArena Pharmaceuticals to Present Additional Pre-Clinical Data on Ralinepag for Treatment of Pulmonary Arterial Hypertension at International Congress of the European Respiratory Society - September 6 at 3:57 PM logoArena Pharmaceuticals, Inc. (ARNA) Receives Average Recommendation of "Buy" from Brokerages - September 5 at 8:54 AM logoArena Pharmaceuticals to Participate in Upcoming Investor Conferences - PR Newswire (press release) - August 29 at 9:22 PM logoArena Pharmaceuticals to Participate in Upcoming Investor Conferences - August 29 at 4:21 PM logoArena Pharmaceuticals, Inc. (ARNA) Short Interest Update - August 28 at 1:48 AM logoArena Pharmaceuticals to Present Additional Pre-Clinical Data on Ralinepag for Treatment of Pulmonary Arterial ... - PR Newswire (press release) - August 23 at 9:11 PM logoArena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : August 23, 2017 - August 23 at 4:10 PM logoArena Pharmaceuticals to Present Additional Pre-Clinical Data on Ralinepag for Treatment of Pulmonary Arterial Hypertension at European Society of Cardiology Congress - August 23 at 8:28 AM logoHeron Therapeutics (HRTX) & Arena Pharmaceuticals (ARNA) Head-To-Head Contrast - August 22 at 10:32 AM logoBiotech Stock Performance Review -- Aralez Pharma, Arena Pharma, Arrowhead Pharma, and Aviragen Therapeutics - PR Newswire (press release) - August 16 at 9:29 PM logoArena Pharmaceuticals, Inc. (NASDAQ:ARNA) Sees Large Decline in Short Interest - August 13 at 2:20 AM logo Analysts Expect Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Will Announce Earnings of -$0.69 Per Share - August 12 at 6:18 PM logoArena Pharmaceuticals, Inc. (NASDAQ:ARNA) Receives Consensus Rating of "Buy" from Analysts - August 11 at 5:06 PM logoCantor Fitzgerald Equities Analysts Reduce Earnings Estimates for Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) - August 10 at 1:50 PM logoArena Pharmaceuticals, Inc. Forecasted to Post Q3 2017 Earnings of ($0.69) Per Share (NASDAQ:ARNA) - August 10 at 12:10 PM logoEdited Transcript of ARNA earnings conference call or presentation 7-Aug-17 8:30pm GMT - August 9 at 9:15 PM logoThe 1 Very Clear Reason Arena Pharmaceuticals, Inc. Skyrocketed 41% in July - Motley Fool - August 9 at 4:12 PM logoThe 1 Very Clear Reason Arena Pharmaceuticals, Inc. Skyrocketed 41% in July - August 9 at 2:04 PM logoArena Pharmaceuticals, Inc. (ARNA) Stock Rating Reaffirmed by Needham & Company LLC - August 9 at 12:38 AM logoArena Pharmaceuticals (ARNA) Q2 Loss Wider than Expected - Nasdaq - August 8 at 3:53 PM logoArena Pharmaceuticals' (ARNA) CEO Amit Munshi on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha - August 8 at 2:57 AM logoArena Pharmaceuticals, Inc. (ARNA) Issues Quarterly Earnings Results - August 7 at 5:14 PM logoArena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2017 Financial Results - August 7 at 4:53 PM logoArena Pharmaceuticals reports 2Q loss - August 7 at 4:53 PM logoArena Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ARNA) : August 4, 2017 - August 3 at 10:26 PM logoWhat's in Store for Arena (ARNA) this Earnings Season? - August 2 at 4:53 PM logoWhat's in Store for Arena (ARNA) this Earnings Season? - August 2 at 4:53 PM logoArena Pharmaceuticals to Release Second Quarter 2017 Financial Results and Provide Corporate Update on Monday ... - PR Newswire (press release) - August 1 at 5:00 PM



Arena Pharmaceuticals (ARNA) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.